Summary & Overview
HCPCS J2503: Injection, pegaptanib sodium, 0.3 mg
HCPCS Level II code J2503 denotes an injection of pegaptanib sodium, 0.3 mg per unit, used in ophthalmic care such as intravitreal therapy. Nationally, this code matters for payers and providers managing specialty ophthalmic pharmaceuticals administered in outpatient or ambulatory settings. Accurate coding impacts coverage determinations, claim adjudication, and tracking of utilization for vision-preserving therapies.
Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J2503 represents clinically, typical sites of service, and the payer landscape relevant to billing and reimbursement. The publication summarizes common billing considerations and presents benchmarks where available, highlights pertinent policy updates affecting HCPCS Level II billing for ophthalmic injections, and provides clinical context for when this medication is administered.
This resource is intended for billing professionals, practice managers, and clinicians who need a national-level reference for coding and payor interactions related to intravitreal pegaptanib sodium administration. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2503 represents the injectable medication pegaptanib sodium, dosed per 0.3 mg for each billed unit. This code is used to report administration of the therapeutic agent indicated for ophthalmic conditions where intravitreal injection of pegaptanib sodium is clinically appropriate.
-
Service type: Injection
-
Typical site of service: Ambulatory ophthalmology clinics or outpatient procedure settings (intravitreal injection in an office or clinic)
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration presenting with decreased central vision, distortion (metamorphopsia), or new central scotoma. Ophthalmology clinic workflow: initial evaluation includes visual acuity, dilated fundus exam, optical coherence tomography (OCT) to assess subretinal/intraretinal fluid and choroidal neovascularization, and fluorescein angiography as indicated. After informed consent and verification of indication, the patient undergoes an intravitreal injection of J2503 (pegaptanib sodium, 0.3 mg) in a procedure room or minor procedure suite. Pre-procedure steps include topical anesthesia, antiseptic preparation (povidone-iodine), and sterile drape; post-injection care includes intraocular pressure check, topical antibiotic per clinician preference, and scheduling follow-up OCT and visual acuity testing within 4–6 weeks for treatment response and possible repeat injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Service performed by the physician | Use when the reported service is the physician's usual service. |
22 | Increased procedural services |